Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Generics and Biosimilars in Dermatology: Improving Access, Competition, and Affordability
Description
The speaker explains how generics and biosimilars improve patient access, competition, and affordability, especially in dermatology. Generics are small-molecule drugs approved through NDA pathways and can usually be substituted at the pharmacy because they are expected to have the same active ingredient, safety, and clinical effect as the brand product. Their broad adoption has driven major savings, accounting for most U.S. prescriptions but only a small share of spending, and multiple manufacturers also help reduce shortage risk. Biosimilars are the larger-molecule counterpart for biologics approved through BLA pathways; they must be highly similar to a reference biologic and may be designated interchangeable. The talk highlights that dermatology includes many complex products, such as topical formulations, combination products, and specialty biologics, making approval pathways more challenging. FDA efforts like GDUFA fund research and product-specific guidances, including in vitro and Q1/Q2/Q3 approaches that can replace more burdensome clinical endpoint studies for many topical products. The speaker notes that biologics make up a large and growing share of U.S. medicine spending and that dermatology spending, especially in Medicare Part D, has risen sharply due to specialty drugs. Biosimilars can create substantial savings, but uptake depends on reimbursement, contracting, and site-of-care dynamics. The presentation closes by emphasizing that understanding substitution rules and payer factors can help improve access, and it ends with a brief note that FDA is hiring dermatologists.
View moreConclusions
- Generic drugs improve access by delivering the same active ingredients and clinical performance as brand products at much lower cost.
- As more generic manufacturers enter a market, prices tend to fall sharply and supply resilience improves, reducing shortage risk.
- Most generic drugs can be approved through bioequivalence-based pathways that avoid unnecessary clinical endpoint trials.
- Complex generic products require tailored regulatory science, product-specific guidance, and early scientific engagement to identify the right approval pathway.
- FDA-funded research through GDUFA has expanded the toolbox for generic development and produced thousands of product-specific guidances, many for complex products.
- For topical dermatology drugs, in vitro Q1/Q2/Q3-based approaches are increasingly preferred over comparative clinical trials when they can better demonstrate equivalence.
- Newer transparency requirements are intended to make generic product development and substitution decisions clearer for certain complex drugs.
- Dermatology drug spending is increasingly driven by expensive specialty therapies, especially biologics, creating significant affordability and access challenges.
- Biologics are structurally more complex, harder and more expensive to manufacture, and therefore require distinct biosimilar pathways rather than standard generic pathways.
- Biosimilars can generate substantial savings and reach meaningful market share, but uptake depends heavily on reimbursement, contracting, site-of-care, and substitution rules.
- The rise of specialty drug spending in dermatology suggests that biosimilars are an important but operationally complex lever for improving patient access.
- FDA Office of Generic Drugs 2022 Annual Report.
- FDA Generic Drugs Q&A.
- Congressional Research Service; FDA analysis; 2020 JAAD reference.
- Raney S, Luke MC. JAAD, 2020.
- Luke MC. Eur J Pharm Sci, 2024.
- IQVIA Institute. Biosimilars in the United States 2023–2027.
- Kong EL, Mostaghimi A. JAMA Dermatology, 2025.
- JAMA Dermatology 2024 economic evaluation using efficiency frontiers and estimated rebates.